Fundz

Eikon Therapeutics

Millbrae, California, United States · Biotechnology, Health Care, Therapeutics

Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to pe

Key facts

Headquarters
Millbrae, California, United States
Employees
390
Industries
Biotechnology, Health Care, Therapeutics
Status
Public (EIKN)
Website
eikontx.com
LinkedIn
Company page

Recent activity at Eikon Therapeutics

  • : Eikon Therapeutics Appoints Ching-Pin Chang as Chief Scientific Officer
  • : SEC 8-K (8.01): On October 26, 2026, the Company presented updated clinical trial data for EIK1001 at the ESMO Congress, detailing the open-label TeLuRide-005 trial which involved 72 participants with advanced stage 4 non-small cell lung cancer (NSCLC). The data indicates that EIK1001, used in combination with pembrolizumab and chemotherapy, shows a potentially durable effect and a favorable tolerability profile for outpatient administration. At the efficacy data cutoff on October 1, 2026, the combination therapy yielded a 63.1% objective response rate (ORR) and a 89.2% disease control rate (DCR). The trial is significant as it could position EIK1001 as a key differentiator in the treatment of NSCLC compared to previous therapies, especially considering the manageable adverse events associated with the drug regimen. This strategic update holds potential implications for future treatment protocols and market positioning.
  • : SEC 8-K (8.01): On October 23, 2026, the Company presented significant clinical data regarding EIK1003, a selective non-brain-penetrant PARP1 inhibitor, during the 2026 European Society for Medical Oncology Congress. Updated results for EIK1003, which has been administered to 65 participants suffering from various cancers, indicate that it was well-tolerated across multiple dose levels and demonstrated promising antitumor activity in combination with the hormonal agent abiraterone and weekly paclitaxel. The objective response rate (ORR) was reported at 14.3% overall in efficacy-evaluable participants, with higher responses noted in PARP-naïve patients. This presentation marks a continuation of data expansion from previously reported findings and could have substantial implications for the treatment landscape of tumors with specific genetic backgrounds.
  • : SEC 8-K (7.01): On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentation to reflect recent developments and strategic initiatives. This updated presentation, which is included as Exhibit 99.1 in the filing, is aimed at providing shareholders and stakeholders with current insights into the company's operations and future direction. The filing clarifies that the information is being 'furnished' rather than 'filed' to mitigate liabilities under certain sections of the Securities Exchange Act and the Securities Act. The updated corporate presentation is significant for informing investors of Eikon's performance and strategic positioning.
  • : SEC 8-K (5.02): Effective July 31, 2026, Leon Chen, Ph.D., and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. The resignations were not due to any disagreements with the Company on its operations, policies, or practices. This change in leadership could have implications for the governance structure and strategic direction of the Company as it transitions to new board members post-resignation.
  • : SEC 8-K (5.02):
  • : SEC 8-K (8.01): On May 30, 2026, Eikon Therapeutics, Inc. issued a press release detailing updated data from its Phase 2 trial of EIK1001, which is focused on first-line patients with stage 4 non-small cell lung cancer. The press release also included new data from the Phase 1/2 trial of EIK1003 in patients with advanced solid tumors. These updates were presented at the 2026 American Society of Clinical Oncology Annual Meeting, indicating significant engagement with the oncology community and potential implications for the company's drug development pipeline. The press release is attached as Exhibit 99.2 and represents a key communication for investors and stakeholders regarding the company's clinical progress.
  • : SEC 8-K (7.01): On May 11, 2026, Eikon Therapeutics, Inc. updated its corporate presentation as part of a Regulation FD disclosure. The updated corporate presentation, which is provided as Exhibit 99.2 to this Current Report, is associated with the company's efforts to communicate its current state and future plans to investors and stakeholders, reflecting potential strategic shifts or developments in its operations. This disclosure is intended to ensure that all investors have equal access to important corporate information and is crucial in maintaining transparency in light of recent market activities. The press release accompanying the corporate presentation also dates back to May 11, 2026, further emphasizing the timeliness of the information provided.
  • : SEC 8-K (5.03): Eikon Therapeutics, Inc. has filed an amended and restated certificate of incorporation and amended and restated bylaws, both effective as of February 6, 2026, in connection with the closing of its initial public offering (IPO). The company's board of directors and stockholders approved these changes to be effective immediately prior to the IPO closing. This strategic move positions Eikon Therapeutics for enhanced operational governance after entering the public market, aligning its corporate structure with new business requirements and reporting standards.
  • : Eikon Therapeutics

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Eikon Therapeutics funding history

DateRoundAmount
Feb 2025Series D$350.7M
Feb 2025Venture$350.7M
May 2023Venture$140.8M
Jan 2022Venture$517.8M
Jan 2022Series B$517.8M

Leadership

  • Dror Berman, Director
  • Leon Chen, Executive Officer, Director
  • Adam Goulburn, Director
  • Roger Perlmutter, Executive Officer, Director
  • James Tananbaum, Director
  • Ching-Pin Chang, Chief Scientific Officer
  • Roger M. Perlmutter, President
  • Michael A. Klobuchar, Chief Operating Officer
  • Benjamin Thorner, Executive Officer

Verified email and direct lines for Eikon Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Eikon Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Eikon Therapeutics in the news

Companies similar to Eikon Therapeutics

About Eikon Therapeutics: questions and answers

What does Eikon Therapeutics do?

Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to pe

Where is Eikon Therapeutics headquartered?

Eikon Therapeutics is headquartered in Millbrae, California, United States.

How many employees does Eikon Therapeutics have?

Eikon Therapeutics has about 390 employees.

Has Eikon Therapeutics raised funding?

Yes. Fundz has recorded 5 funding events for Eikon Therapeutics. The most recent, Series D of $350.7M, was in Feb 2025.

Who leads Eikon Therapeutics?

Roger M. Perlmutter is a President at Eikon Therapeutics.

What is the latest news on Eikon Therapeutics?

On Sep 3, 2026, Eikon Therapeutics Appoints Ching-Pin Chang as Chief Scientific Officer

Is Eikon Therapeutics a public company?

Yes. Eikon Therapeutics is publicly traded under the ticker EIKN.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Eikon Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.